Bronchiectasis
Aksamit TR et al (2017) Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest;151(5):982-992
Alberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, Fardon TC, Rutherford R, Pesci A, Restrepo MI, Sotgui G, Chalmers JD (2016), Clinical phenotypes in adult patients with bronchiectasis Eur Respir J Apr,47(4):1113-22
Altenburg J et al (2013). Effect of azithromycin treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomised controlled trial. JAMA; 12;309
Baris S, Ozen A, Ercan H, Karakoc-Aydiner E, Cagan H, Ozdemir C, Barlan M, Bahceciler NN, Barlan IB (2011). Osteoporosis: an ignored complication of CVID. Pediatr Allergy Immunol Nov;22(7):676-83
Bibby, S, Milne, R, Beasley, R (2015) Hospital admissions for non-cystic fibrosis bronchiectasis in New Zealand. NZMJ 128(1421):30-38.
Bilton D, Tino G, Barker AF, et al. (2014) Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomised, controlled trial Thorax. Published Online First: September 2014 doi:10.1136/thoraxjnl2014-205587
Bilton D, Henig N, Morrissey B, Gotfried M (2006) Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest Nov;130(5):1503-10
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT (2014) The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. Mar 1;189(5):576-85doi:1
Chalmers et al (2016) The EMBARC European Bronchiectasis Registry: protocol for an international observational study.
Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, et al.(2010) Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust;193(6):356-65.
Chang AB, Grimwood K, Mulholland EK, Torzillo PJ (2002). Bronchiectasis in indigenous children in remote Australian communities. Med J Aust 2002;177:200-4
Chang A, Masel J, Boyce NC, Wheaton G & Torzillo P (2003). Non-CF bronchiectasis: clinical and HRCT evaluation. Pediatr Pulmonol 35:477–83.
Chang AB, Marsh RL, Upham JW, Hoffman LR, Smith-Vaughan H, Holt D, Toombs M, Byrnes C, Yerkovich ST, Torzillo PJ, O’Grady KA, Grimwood K (2015)Toward making inroads in reducing the disparity of lung health in Australian Indigenous and New Zealand Māori children. Pediatr Pulmonol 3: 9Retrieved February 2015 from http://dx.doi.org/10.3389/fped.2015.00009
A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. Anne B Chang, Scott C Bell, Cass A Byrnes, Keith Grimwood, Peter W Holmes, Paul T King, John Kolbe, Louis I Landau, Graeme P Maguire, Malcolm I McDonald, David W Reid, Francis C Thien and Paul J Torzillo (2010) Med J Aust ; 193 (6): 356-3650.1164/rccm.201309-1575OC.
Crengle, S, La-Yee, R, Davis, P, Pearson, JA (2006)Comparison of Māori and non-Māori visits to doctors. NatMedCaReport6
Desai M, Weller PH, Spencer DA (1995) Clinicial benefit from nebulized human recombinant DNase in Kartagener’s syndrome. Paediatr Pulmonol. Nov;20(5):307-8
El-Abiad NM, Clifton S, Nasr SZ (2007) Long-term use of nebulized human recombinant DNase in two siblings with primary ciliary dyskinesia Respir Med. Oct;101(10):2224-6
Elborn JS and Bell SC (2007) Pulmonary exacerbations in cystic fibrosis and bronchiectasis Thorax Apr;62(4):288290 doi:10.1136/thx.2006.065664 PMCID:PMC2092464
Finch S et al (2015) A comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. Ann Am Thorac Soc;12:1602-1611
Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton (2014) Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection Am J Respir Crit Care Med. Apr 15;189(8):975-82
Hill AT et al (2017) Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017. Print 2017 Jun.
Kapur N, Masters IB, Chang AB (2009). Exacerbations in non-cystic fibrosis bronchiectasis: clinical features and investigations. Resp Med 103:1681-1687
King P, Holdsworth S, Freezer N, Villanueva E, Holmes P (2006) Characterisation of the onset and presenting clinical features of adult bronchiectasis. Resp Med 100: 2183-2189
Lee A, Button B, Denehy L (2008). Current Australian and NZ physiotherapy practice in the management of patients with chronic bronchiectasis and COPD. NZ J Physiother 36(2):49-58.
Loebinger MR, Wells AU, Hansell DM et al (2009) Mortality in bronchiectasis: a long-term study assessing the factors influencing survival Eur Resp J 34:843-849
Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón RM, Máiz Carro L, de la Rosa Carrillo D, Olveira C (2014) .Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. May;43(5):1357-67.
McDonnell M et al (2016) Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts. Thorax Dec;71(12):1110-1118
McDonnell M et al (2016) Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med Dec;4(12):969-979. doi: 10.1016/S2213-2600(16)30320-4. Epub 2016 Nov 16.
McDonnell MJ et al (2015). Non-cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med;109:716-726
McShane PJ, Naureckas ET, Tino G, Strek ME (2013). Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 188;647-656
Minor J, Karadzinska-Bislimorska J, Vasilevska K, Stoleski S, Mijakoski D (2015) Assessment of the Non-Cystic Fibrosis Bronchiectasis Severity:The FACED score vs the Bronchiectasis Severity Index. The Open Respiratory Medicine Journal !SSN:1874-3064,Vol9
Murray et al (2009). Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J Vol34:no2,361-364
National Blood Authority. Access to intravenous immunoglobulin. Available from: https://www.blood.gov.au/Intravenous-Ig. Accessed July 2018.
O’Donnell AE, Barker AF, Ilowite JS, Fick RB (1998) Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase. Chest May 113 (5):1329-34
O’Leary CJ, Wilson CB, Hansell DM, Cole PJ, Wilson R, Jones PW (2002): Relationship between psychological well-being and lung health status in patients with bronchiectasis. Respir Med 96:686-692 Ozalp O, Inal-Ince, D, Calik E, Vardar-Yagli N, Saglam M, Savci S, Arikan H, Bosnak-Guclu M, Coplu L.
Onen ZP, Gulbay BE, Sen E et al (2007). Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med 101:1390-1397
Pasteur MC, Bilton D, Hill AT. (2010) British Thoracic Society guideline for non-CF bronchiectasis. Thorax.;65 Suppl 1(7):i1-58.
Perez E, Orange J, Bonilla F et al.(2017) Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 7;139:S1-46.
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al.(2017) European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J;50(3).
Quint JK, Millett E, Hurst JR, Smeeth L, Brown J (2012); Time trends in incidence and prevalence of bronchiectasis in the UK. Thorax 67:A138 doi:10.1136/thoraxjnl-2012-202678.233
Quint JK,, , , , , , Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.Eur Respir J:Jan;47(1):186-93.
Rachel Thomson and Wing-Wai Yew (2009) When and how to treat pulmonary non-tuberculous mycobacterial diseases. Respirology 14,12-26 doi:10.1111/j.1440-1843.2008.01408.x
Roberts ME, Lowndes L, Milne DG, Wong CA (2012) Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Internal Medicine Journal:42(6):e129-36.
Rogers G et al (2014) A novel microbiota stratification system predicts future exacerbations in bronchiectasis.Ann Am Thorac Soc. 2014 May;11(4):496-503. doi: 10.1513/AnnalsATS.201310-335OC.
Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R (2012). Trends in bronchiectasis amongst Medicare beneficiaries in the United States, 2000 to 2007. Chest 142(2):432-9.
Shoemark AL, Ozerovitch L, Wilson R (2007). Aetiology in adult patients with bronchiectasis. Respir Med 101:1163-1170
Stockley RA, Bayley D, Hill SL et al (2001). Assessment of airway neutrophils by sputum colour:correlation with airways inflammation. Thorax 56:366-72
Twiss, J, Metcalfe R, Edwards E & Byrnes C (2005). New Zealand national incidence of bronchiectasis “too high” for a developed country. Arch Dis Child 90:737–40.
Visser SK et al (2019) Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. Respir Med 155:97-103
Weycker D, Edelsberg J, Oster G, et al. (2005) Prevalence and economic burden of bronchiectasis. Clin Pulm Med; 12: 205–209
Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ (1996) Short-term recombinant human DNase in bronchiectasis. Am J Respir Crir Care Med. Aug;154(2Pt 1):413-7
Wilson R et al (2016) Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respir Med. Aug;117:179-89. doi: 10.1016/j.rmed.2016.06.007. Epub 2016 Jun 7
